In a phase 2 clinical trial, patients with metastatic papillary [...]
Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]